A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

BACKGROUND: Treatment-resistant depression (TRD) is a substantial public health burden, but current treatments have limited effectiveness. The aim was to investigate the safety and potential antidepressant effects of the serotonergic psychedelic drug 5-MeO-DMT in a vaporized formulation (GH001) in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Reckweg, Johannes T., van Leeuwen, Cees J., Henquet, Cécile, van Amelsvoort, Therese, Theunissen, Eef L., Mason, Natasha L., Paci, Riccardo, Terwey, Theis H., Ramaekers, Johannes G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319409/
https://www.ncbi.nlm.nih.gov/pubmed/37409159
http://dx.doi.org/10.3389/fpsyt.2023.1133414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319409/
https://www.ncbi.nlm.nih.gov/pubmed/37409159
http://dx.doi.org/10.3389/fpsyt.2023.1133414

Ejemplares similares